GBEMX
Price
$19.29
Change
+$0.05 (+0.26%)
Updated
Dec 20 closing price
RNWFX
Price
$77.72
Change
+$0.12 (+0.15%)
Updated
Dec 20 closing price
Ad is loading...

GBEMX vs RNWFX

Header iconGBEMX vs RNWFX Comparison
Open Charts GBEMX vs RNWFXBanner chart's image
Victory Sophus Emerging Markets A
Price$19.29
Change+$0.05 (+0.26%)
VolumeN/A
CapitalizationN/A
American Funds New World R5
Price$77.72
Change+$0.12 (+0.15%)
VolumeN/A
CapitalizationN/A
GBEMX vs RNWFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
GBEMX vs. RNWFX commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GBEMX is a StrongBuy and RNWFX is a Buy.

FUNDAMENTALS
Fundamentals
RNWFX has more cash in the bank: 62.2B vs. GBEMX (352M). GBEMX pays higher dividends than RNWFX: GBEMX (2.16) vs RNWFX (1.51). GBEMX was incepted earlier than RNWFX: GBEMX (28 years) vs RNWFX (23 years). GBEMX is a more actively managed with annual turnover of: 72.00 vs. RNWFX (32.00). RNWFX has a lower initial minimum investment than GBEMX: RNWFX (250) vs GBEMX (2500). GBEMX annual gain was more profitable for investors over the last year : 7.75 vs. RNWFX (5.86). RNWFX return over 5 years is better than : 14.39 vs. GBEMX (-0.19).
GBEMXRNWFXGBEMX / RNWFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence28 years23 years-
Gain YTD6.0084.549132%
Front LoadN/AN/A-
Min. Initial Investment25002501,000%
Min. Initial Investment IRA1000N/A-
Net Assets352M62.2B1%
Annual Yield % from dividends2.161.51143%
Returns for 1 year7.755.86132%
Returns for 3 years-7.51-5.10147%
Returns for 5 years-0.1914.39-1%
Returns for 10 years26.6242.6762%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VTRS12.520.39
+3.22%
Viatris
TEO11.890.14
+1.19%
Telecom Argentina SA
DX12.570.14
+1.13%
Dynex Capital
INTT7.680.04
+0.52%
inTEST Corp
VIRX0.21N/A
-1.87%
Viracta Therapeutics